Neoadjuvant tislelizumab with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-1): a phase 2 clinical trial

Abstract Despite receiving standard treatments, patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) often still face significant risks of disease recurrence or metastasis. In this phase II neoCHANCE-1 study (NCT05517330), we evaluated the efficacy and safety of the dual-t...

Descripció completa

Dades bibliogràfiques

Autors principals:	Zhi-gong Wei, Hui-jiao Chen, De-juan Wang, Zheng Jiang, Yi-yan Pei, Le-yu Li, Feng Wang, Jing Jin, Zhe-ran Liu, Fei Chen, Jun Liu, Xing-chen Peng
Format:	Artigo
Idioma:	Inglês
Publicat:	Nature Portfolio 2025-10-01
Col·lecció:	Nature Communications
Accés en línia:	https://doi.org/10.1038/s41467-025-63978-y
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!